A number of other equities research analysts have also commented on CTSO. B. Riley initiated coverage on shares of Cytosorbents in a research note on Friday, June 12th. They issued a buy rating and a $16.00 price objective on the stock. Maxim Group initiated coverage on shares of Cytosorbents in a research note on Thursday, May 7th. They issued a buy rating and a $14.00 price objective on the stock. HC Wainwright upped their price objective on shares of Cytosorbents from $13.00 to $14.00 and gave the company a buy rating in a research note on Wednesday, May 6th. Finally, Dawson James reaffirmed a buy rating and issued a $17.00 price objective (up from $15.00) on shares of Cytosorbents in a research note on Monday, March 9th. Six analysts have rated the stock with a buy rating, Cytosorbents currently has a consensus rating of Buy and a consensus target price of $15.25.
CTSO opened at $9.79 on Tuesday. Cytosorbents has a fifty-two week low of $3.49 and a fifty-two week high of $11.24. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.27 and a quick ratio of 3.10. The firm has a market capitalization of $345.09 million, a price-to-earnings ratio of -17.80 and a beta of 0.58. The company’s 50 day moving average price is $9.72 and its two-hundred day moving average price is $6.72.
Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Tuesday, May 5th. The medical research company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.04. Cytosorbents had a negative net margin of 62.65% and a negative return on equity of 165.86%. The firm had revenue of $8.71 million for the quarter, compared to analyst estimates of $7.14 million. As a group, equities research analysts predict that Cytosorbents will post -0.37 EPS for the current year.
In related news, COO Vincent Capponi sold 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $10.00, for a total transaction of $100,000.00. Following the transaction, the chief operating officer now owns 427,649 shares in the company, valued at approximately $4,276,490. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.70% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its position in shares of Cytosorbents by 51.9% during the 1st quarter. Royal Bank of Canada now owns 8,857 shares of the medical research company’s stock valued at $68,000 after acquiring an additional 3,027 shares during the period. Zebra Capital Management LLC acquired a new position in Cytosorbents during the first quarter worth $87,000. Advisor Group Holdings Inc. acquired a new position in Cytosorbents during the first quarter worth $281,000. Soleus Capital Management L.P. acquired a new position in Cytosorbents during the first quarter worth $538,000. Finally, Wells Fargo & Company MN raised its holdings in Cytosorbents by 43.3% during the first quarter. Wells Fargo & Company MN now owns 33,682 shares of the medical research company’s stock worth $260,000 after buying an additional 10,172 shares during the last quarter. Institutional investors own 27.54% of the company’s stock.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Recommended Story: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.